MedPath

浙江核力欣健药业有限公司

Ownership
-
Established
2014-03-11
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

5

NMPA:5

Drug Approvals

Vonoprazan Fumarate Tablets

Product Name
富马酸伏诺拉生片
Approval Number
国药准字H20254207
Approval Date
May 20, 2025
NMPA

Vonoprazan Fumarate Tablets

Product Name
富马酸伏诺拉生片
Approval Number
国药准字H20254206
Approval Date
May 20, 2025
NMPA

Teprenone Capsules

Product Name
替普瑞酮胶囊
Approval Number
国药准字H20244437
Approval Date
Jul 9, 2024
NMPA

Loratadine Syrup

Product Name
氯雷他定糖浆
Approval Number
国药准字H20233429
Approval Date
Apr 11, 2023
NMPA

Levocetirizine Dihydrochloride Oral Solution

Product Name
盐酸左西替利嗪口服溶液
Approval Number
国药准字H20223974
Approval Date
Dec 30, 2022
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.